← All trials
NCT04891809
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 20, 2021
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2028
- First posted
- May 18, 2021
- Last posted
- Nov 1, 2021
- Enrollment
- 198
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Arbeitsgemeinschaft medikamentoese TumortherapieLead sponsor
- Assign Clinical Research GmbHCollaborator
- SanofiCollaborator
- Medical University of ViennaCollaborator
- University of NavarraCollaborator
- Wilhelminen Cancer Research Institute, Clinic OttakringOverall official - principal investigator
- WiSP GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.